Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • moem
    Junior Member
    • Nov 2015
    • 3

    #1

    edgeR and MA-plot question

    Hi,

    I am running edgeR and used plotSmear to visualize my results. When coloring only the genes that are DE by FDR<0.05 I see that many genes have a higher fold change than some of the DE genes and that some of the DE genes have a low fold change. This is only the case when I use estimateGLMTagwiseDisp and not when I use estimateGLMCommonDisp. Does this mean that using common dispersion is the best? I only have cases and controls in my data so I guess it should be good enough but I always thought estimating tagwise dispersion was better?

    Also:
    It also seems like ~90 % of my genes are up-regulated. I tried all the different normalization options but the results seem to be the same. Can this be true or could something be wrong with my data? Any way of testing that?
    Last edited by moem; 11-18-2015, 05:57 AM.
  • N311V
    Member
    • Jul 2013
    • 34

    #2
    I can't comment on your edgeR problem but maybe try using limma and see if a different approach gives the same result.

    Regarding 90% up-regulated, what are the differences between your cases and controls? For example, were they sequenced at the same time, extracted at the same time, etc.

    Comment

    • mastal
      Senior Member
      • Mar 2009
      • 666

      #3
      Does it make biological sense?

      Is the condition you are comparing between cases and controls one where you might expect the majority of the genes to be upregulated?

      Comment

      • moem
        Junior Member
        • Nov 2015
        • 3

        #4
        Thank you for your answers. I have run limma and DESeq now and it gives the same sort of answers with regards to the amount of up/down-regulation.

        I was wondering if anyone could see if my code makes sense:

        condition <- relevel(factor(input$condition),ref=”Control”)
        design <- model.matrix(~condition)

        “design” then lists “Intercept” and “ConditionCase”.

        e <- DGEList(counts=countstable)
        e <- calcNormFactors(e, method=”TMM”)
        e <- estimateGLMCommonDisp(e, design)
        e <- estimateGLMTrendedDisp(e, design)
        e <- estimateGLMTagwiseDisp(e, design)
        efit <- glmFit(e, design)
        efit <- glmLRT(efit, coef="ConditionCase")

        The logFCs are then mainly positive. My interpretation is then up-regulation in ConditionCase.
        Last edited by moem; 11-24-2015, 12:42 AM.

        Comment

        • N311V
          Member
          • Jul 2013
          • 34

          #5
          The result seems reasonable.

          Is there any other reason you can think of that might cause systematic up regulation?

          Were controls and treatments extracted at the same time? Sequenced at the same time? Are there age differences between treatments? Sex differences between treatments?

          Comment

          • moem
            Junior Member
            • Nov 2015
            • 3

            #6
            Thanks for looking at my code.

            Can't think of any reasons, but this is not a condition I know much about.

            Extraction and sequencing at the same time and same sex. No systematic difference in age between groups.

            Comment

            Latest Articles

            Collapse

            • SEQadmin2
              Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
              by SEQadmin2



              CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

              Despite this, “CRISPR helped turn genome editing from a specialized technique into
              ...
              07-31-2026, 11:01 AM
            • SEQadmin2
              Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
              by SEQadmin2


              Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

              The systematic characterization of the human proteome has
              ...
              07-20-2026, 11:48 AM
            • SEQadmin2
              Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
              by SEQadmin2



              Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
              ...
              07-09-2026, 11:10 AM

            ad_right_rmr

            Collapse

            News

            Collapse

            Topics Statistics Last Post
            Started by SEQadmin2, Today, 07:41 AM
            0 responses
            9 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 08-03-2026, 10:13 AM
            0 responses
            24 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-31-2026, 02:55 AM
            0 responses
            38 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-24-2026, 12:17 PM
            0 responses
            25 views
            0 reactions
            Last Post SEQadmin2  
            Working...